GEM PREMIER CHEMSTAT PAK
Report
- Report Number
- 1217183-2025-00009
- Event Type
- Malfunction
- Date Received
- March 12, 2025
- Date of Event
- March 2, 2024
- Report Date
- March 12, 2025
- Manufacturer
- INSTRUMENTATION LABORATORY CO.
- Product Code
- JFY
- UDI-DI
- 08426951070800
- PMA / PMN Number
- K223090
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- UK
- Reporter Occupation
- OTHER HEALTH CARE PROFESSIONAL
- Health Professional
- Yes
Narratives
AT THE TIME OF THE REPORTED COMPLAINT, INSTRUMENTATION LABORATORY CO. CONDUCTED A COMPREHENSIVE INVESTIGATION, INCLUDING A REVIEW OF THE DATA FROM THE GEM PREMIER CHEMSTAT PAK (CARTRIDGE) IN QUESTION. THE CUSTOMER PROVIDED THE LABORATORY RESULTS AND A PATIENT MEDICATION LIST, WHICH INCLUDED PARACETAMOL. HOWEVER, THE GROUP MEAN BIASES FOR SAMPLES WITH AND WITHOUT PARACETAMOL WERE ALMOST THE SAME (1.02 VS. 0.95 MG/DL), AND THE ROOT CAUSE OF THE HIGH CREATININE RESULTS COULD NOT BE CONCLUSIVELY DETERMINED. IN ADDITION, DURING VERIFICATION TESTING, NO INTERFERENCE WAS OBSERVED WHEN INTERFERENCE TESTING WAS PERFORMED WITH ACETAMINOPHEN WHICH IS ALSO APPLICABLE TO PARACETAMOL. AS A RESULT, THE COMPLAINT WAS CLOSED, AND NO REMEDIAL ACTION WAS DEEMED NECESSARY. IMPORTANT NOTE: INSTRUMENTATION LABORATORY CO. RECENTLY CONDUCTED A SELF-ASSESSMENT OF ITS QUALITY MANAGEMENT SYSTEM AS PART OF ITS ONGOING COMPLIANCE AND QUALITY PROGRAM DUE DILIGENCE. ONE ASPECT OF THIS ASSESSMENT WAS TO PERFORM A RETROSPECTIVE REVIEW OF PRODUCT COMPLAINTS RECEIVED OVER THE PAST TWO YEARS, TO ASSESS IF ANY COMPLAINTS SHOULD HAVE BEEN REPORTED TO FDA FOLLOWING THE FDA GUIDANCE, "MEDICAL DEVICE REPORTING FOR MANUFACTURERS". AS PART OF THIS ASSESSMENT, WE IDENTIFIED A SMALL NUMBER OF COMPLAINTS THAT REQUIRE RETROSPECTIVE REPORTING. PLEASE BE ASSURED THAT INSTRUMENTATION LABORATORY TAKES ITS REGULATORY RESPONSIBILITIES TO THE FDA AND ITS CUSTOMERS SERIOUSLY AND STRIVES TO PRODUCE ONLY THE HIGHEST QUALITY DEVICES. THE NUMBER OF LATE REPORTED COMPLAINTS IS LESS THAN 0.005% OF THE ANNUAL COMPLAINT VOLUME RECEIVED AND A CAPA HAS BEEN INITIATED TO MITIGATE FUTURE OCCURRENCES. FURTHERMORE, THE COMPANY HAS AND WILL CONTINUE TO DEDICATE THE NECESSARY FINANCIAL AND PERSONNEL RESOURCES (AND MANAGEMENT OVERSIGHT) TO COMPLETE THESE ACTION PLANS IN A TIMELY MANNER.
A CUSTOMER REPORTED THAT CREATININE RESULTS FROM A GEM PREMIER CHEMSTAT PAK (CARTRIDGE) WERE SIGNIFICANTLY HIGHER THAN THE LABORATORY RESULTS. NO PATIENT IMPACT WAS REPORTED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1112903 | GEM PREMIER CHEMSTAT PAK | ENZYMATIC METHOD, CREATININE | JFY | INSTRUMENTATION LABORATORY CO. | 240118A | 08426951070800 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | NA | Unknown |